PuSH - Publikationsserver des Helmholtz Zentrums München

Klüpfel, J.* ; Koros, R.C.* ; Dehne, K.* ; Ungerer, M.* ; Würstle, S.* ; Mautner, J. ; Feuerherd, M. ; Protzer, U. ; Hayden, O.* ; Elsner, M.* ; Seidel, M.*

Automated, flow-based chemiluminescence microarray immunoassay for the rapid multiplex detection of IgG antibodies to SARS-CoV-2 in human serum and plasma (CoVRapid CL-MIA).

Anal. Bioanal. Chem., DOI: 10.1007/s00216-021-03315-6 (2021)
Verlagsversion DOI
Open Access Gold (Paid Option)
Creative Commons Lizenzvertrag
In the face of the COVID-19 pandemic, the need for rapid serological tests that allow multiplexing emerged, as antibody seropositivity can instruct about individual immunity after an infection with SARS-CoV-2 or after vaccination. As many commercial antibody tests are either time-consuming or tend to produce false negative or false positive results when only one antigen is considered, we developed an automated, flow-based chemiluminescence microarray immunoassay (CL-MIA) that allows for the detection of IgG antibodies to SARS-CoV-2 receptor-binding domain (RBD), spike protein (S1 fragment), and nucleocapsid protein (N) in human serum and plasma in less than 8 min. The CoVRapid CL-MIA was tested with a set of 65 SARS-CoV-2 serology positive or negative samples, resulting in 100% diagnostic specificity and 100% diagnostic sensitivity, thus even outcompeting commercial tests run on the same sample set. Additionally, the prospect of future quantitative assessments (i.e., quantifying the level of antibodies) was demonstrated. Due to the fully automated process, the test can easily be operated in hospitals, medical practices, or vaccination centers, offering a valuable tool for COVID-19 serosurveillance. Graphical abstract.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten [➜Einloggen]
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Automated Analysis Platform ; Covid-19 Serology ; Flow-based Chemiluminescence Microarray Immunoassay ; Rapid Multiplex Antibody Detection ; Sars-cov-2
ISSN (print) / ISBN 1618-2642
e-ISSN 1618-2650
Verlag Springer
Verlagsort Heidelberg
Begutachtungsstatus Peer reviewed
Förderungen Bayerische Forschungsstiftung